Background:Obestatin is a novel hormone derived from preproghrelin, which was reported to inhibit appetite and gastric motility. Study Aim:This study aimed to investigate plasma obestatin levels in obese patients with T2D patients, which had not been studied clearly in last researches. Methods:23 normal weight subjects, 35 obese subjects and 31 obese patients with T2D participated in the study, the body mass index was calculated. Fasting glucose and insulin levels were measured and the homeostasis model assessment of insulin resistance (HOMA-IR) was determined. Plasma obestatin levels were measured with enzyme-linked immune sorbent assay (ELISA). The relationship between plasma obestatin levels and biochemical parameters was also analyzed. Results:Fasting obestatin was significantly lower in obese patients with T2D, comparing to control subjects (mean=6.35 vs12.38ng/ml) and to the non-patients obese group (mean=6.35 vs 7.76 ng/ml). Obestatin levels correlated significantly and negatively with BMI (R=-0. 451; P=0. 01), basal insulin levels (R=-0.737, P<0.0001) and HOMA-IR (R=-0. 764, P<0.0001) in diabetic patients. Conclusion:Our results suggest that obestatin may contribute to body weight regulation, and insulin sensitivity could be affected by obestatin levels.

No abstract